{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:43:45Z","timestamp":1791434625963,"version":"4.3.3"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"suppl 3","funder":[{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["R56 AI111985"],"award-info":[{"award-number":["R56 AI111985"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.1093\/cid\/ciw483","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T07:18:14Z","timestamp":1476429494000},"page":"S102-S109","source":"Crossref","is-referenced-by-count":35,"title":["Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks"],"prefix":"10.1093","volume":"63","author":[{"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam","family":"Pasipanodya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"2016101400180356000_63.suppl_3.S102.1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001965"},{"key":"2016101400180356000_63.suppl_3.S102.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00007-9"},{"key":"2016101400180356000_63.suppl_3.S102.3","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(92)90039-M"},{"key":"2016101400180356000_63.suppl_3.S102.4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1353"},{"key":"2016101400180356000_63.suppl_3.S102.5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181df9070"},{"key":"2016101400180356000_63.suppl_3.S102.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00064-11"},{"key":"2016101400180356000_63.suppl_3.S102.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1470-x"},{"key":"2016101400180356000_63.suppl_3.S102.8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-115"},{"key":"2016101400180356000_63.suppl_3.S102.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.025"},{"key":"2016101400180356000_63.suppl_3.S102.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-008-0778-7"},{"key":"2016101400180356000_63.suppl_3.S102.11","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.171284"},{"key":"2016101400180356000_63.suppl_3.S102.12","unstructured":"World Health Organization. Global tuberculosis report 2015. Geneva, Switzerland: WHO, 2015."},{"key":"2016101400180356000_63.suppl_3.S102.13","unstructured":"Douste-Blazy P . 4,600 pills over two years\u2014there has to be a better way to treat TB. The Guardian. 24 March 2016. Available at: https:\/\/www.theguardian.com\/global-development\/2016\/mar\/24\/pills-treat-tb-research-multi-drug-resistant-tuberculosis. Accessed 20 July 2016."},{"key":"2016101400180356000_63.suppl_3.S102.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70852-7"},{"key":"2016101400180356000_63.suppl_3.S102.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00044812"},{"key":"2016101400180356000_63.suppl_3.S102.16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir658"},{"key":"2016101400180356000_63.suppl_3.S102.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis353"},{"key":"2016101400180356000_63.suppl_3.S102.18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"2016101400180356000_63.suppl_3.S102.19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2675"},{"issue":"suppl 3","key":"2016101400180356000_63.suppl_3.S102.20","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2016101400180356000_63.suppl_3.S102.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"key":"2016101400180356000_63.suppl_3.S102.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ921"},{"key":"2016101400180356000_63.suppl_3.S102.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70264-5"},{"key":"2016101400180356000_63.suppl_3.S102.24","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181df4b9a"},{"key":"2016101400180356000_63.suppl_3.S102.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02784-14"},{"key":"2016101400180356000_63.suppl_3.S102.26","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001114"},{"key":"2016101400180356000_63.suppl_3.S102.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00437-11"},{"key":"2016101400180356000_63.suppl_3.S102.28","doi-asserted-by":"crossref","unstructured":"Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. Concentration-dependent synergy and antagonism of linezolid and moxifloxacin in the treatment of childhood tuberculosis: the dynamic duo. Clin Infect Dis 2016; 63(suppl 3):S88\u201394.","DOI":"10.1093\/cid\/ciw473"},{"issue":"suppl 3","key":"2016101400180356000_63.suppl_3.S102.29","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2016101400180356000_63.suppl_3.S102.30","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/ciw482","article-title":"Linezolid for infants and toddlers with disseminated tuberculosis: first steps","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2016101400180356000_63.suppl_3.S102.31","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciw472","article-title":"A combination regimen design program based on pharmacodynamic target setting for childhood tuberculosis: design rules for the playground","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2016101400180356000_63.suppl_3.S102.32","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku478"},{"key":"2016101400180356000_63.suppl_3.S102.33","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086954.43010.63"},{"key":"2016101400180356000_63.suppl_3.S102.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu868"},{"key":"2016101400180356000_63.suppl_3.S102.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00239-X"},{"key":"2016101400180356000_63.suppl_3.S102.36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu610"},{"key":"2016101400180356000_63.suppl_3.S102.37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00763-10"},{"key":"2016101400180356000_63.suppl_3.S102.38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ427"},{"key":"2016101400180356000_63.suppl_3.S102.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ425"},{"key":"2016101400180356000_63.suppl_3.S102.40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ426"},{"key":"2016101400180356000_63.suppl_3.S102.41","doi-asserted-by":"publisher","DOI":"10.2307\/2280232"},{"key":"2016101400180356000_63.suppl_3.S102.42","unstructured":"Metropolis N . The beginning of the Monte Carlo method. Los Alamos Sci 1987; Special Issue:125\u201330."},{"key":"2016101400180356000_63.suppl_3.S102.43","doi-asserted-by":"publisher","DOI":"10.1118\/1.595681"},{"key":"2016101400180356000_63.suppl_3.S102.44","doi-asserted-by":"publisher","DOI":"10.1016\/0883-2889(91)90053-4"},{"key":"2016101400180356000_63.suppl_3.S102.45","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059659"},{"key":"2016101400180356000_63.suppl_3.S102.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"2016101400180356000_63.suppl_3.S102.47","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"2016101400180356000_63.suppl_3.S102.48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00749-10"},{"key":"2016101400180356000_63.suppl_3.S102.49","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.48.261"},{"key":"2016101400180356000_63.suppl_3.S102.50","first-page":"71","article-title":"Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field","volume":"48","author":"Toyonaga","year":"1995","journal-title":"Jpn J Antibiot"},{"key":"2016101400180356000_63.suppl_3.S102.51","doi-asserted-by":"publisher","DOI":"10.1086\/605576"},{"key":"2016101400180356000_63.suppl_3.S102.52","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl305"},{"key":"2016101400180356000_63.suppl_3.S102.53","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.12.1322.32702"},{"key":"2016101400180356000_63.suppl_3.S102.54","unstructured":"Arguedas A , Dagan R , Rincon G et al . Faropenem pharmacokinetics in AOM children following oral administration of faropenem medoxomil. In: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 2008."},{"key":"2016101400180356000_63.suppl_3.S102.55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01158-15"},{"key":"2016101400180356000_63.suppl_3.S102.56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03461-14"},{"key":"2016101400180356000_63.suppl_3.S102.57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00023-13"},{"key":"2016101400180356000_63.suppl_3.S102.58","first-page":"366","article-title":"Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases","volume":"61","author":"Yokota","year":"2008","journal-title":"Jpn J Antibiot"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/suppl_3\/S102\/7936222\/ciw483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T02:03:34Z","timestamp":1503626614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciw483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":58,"journal-issue":{"issue":"suppl 3","published-online":{"date-parts":[[2016,10,14]]},"published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1093\/cid\/ciw483"],"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw483","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}